Potent, persistent cellular immune responses elicited by sequential immunization of rhesus macaques with Ad5 host range mutant recombinants encoding SIV Rev and SIV Nef

DNA and Cell Biology

Volumn 21, Issue 9, 2002, Pages 627-635

  Patterson, L Jean ^a   Malkevitch, Nina ^a   Zhao, Jun ^a   Peng, Bo ^a   Robert Guroff, Marjorie ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; GAMMA INTERFERON; GENE PRODUCT; NEF PROTEIN; PEPTIDE; REV PROTEIN; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE; VIRUS ENVELOPE PROTEIN; VIRUS VECTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADENOVIRUS 5; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN RECOGNITION; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; GENE REPLICATION; GENETIC CODE; HOST RANGE; IMMUNIZATION; IMMUNOGENICITY; MACACA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECOMBINANT GENE; RHESUS MONKEY; SECRETORY CELL; SIMIAN IMMUNODEFICIENCY VIRUS; VIRUS INFECTION; VIRUS MUTANT;

ADENOVIRIDAE; AIDS VACCINES; ANIMALS; GENE PRODUCTS, ENV; GENE PRODUCTS, NEF; GENE PRODUCTS, REV; GENETIC VECTORS; LEUKOCYTES, MONONUCLEAR; MACACA MULATTA; MEMBRANE GLYCOPROTEINS; MUTATION; SIMIAN IMMUNODEFICIENCY VIRUS; VACCINES, SYNTHETIC; VIRAL ENVELOPE PROTEINS;

ADENOVIRIDAE; ANIMALIA; HUMAN ADENOVIRUS TYPE 5; MACACA; MACACA MULATTA; RNA VIRUSES; SIMIAE; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 0036394608     PISSN: 10445498     EISSN: None     Source Type: Journal    
DOI: 10.1089/104454902760330165     Document Type: Article

References (42)

1. Addo, M. M., Altfeld, M., Rosenberg, E.S., Eldridge, R.L., Philips, M.N., Habeeb, K., Khatri, A., Brander, C., Robbins, G.K., Mazzara, G.P., Goulder, P.J.R., Walker, B.D., and The HIV Controller Study Collaboration. (2001). The HIV-1 regulatory proteins Tat and Rev are frequently targeted by cytotoxic T lymphocytes derived from HIV-1 infected individuals. Proc. Natl. Acad. Sci. USA 98, 1781-1786.
2. Allen, T.M., O'Connor, D.H., Jing, P., Dzuris, J.L., Mothe, B.R., Vogel. T.U., Dunphy, E., Liebl, M.E., Emerson, C., Wilson, N., Kunstman, K.J., Wang, X., Allison, D.B., Hughes, A.L., Desrosiers, R.C., Altman, J.D., Wolinsky, S.M., Sette, A., and Watkins, D.I. (2000). Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature 407, 386-390.
3. Ameisen, J.C., Guy, B., Chamaret, S., Loche, M., Mouton, Y., Neyrinck, J.L., Khalife, J., Leprevost, C., Beaucaire, G., Boutillon, C. Gras-Masse, H., Maniez, M., Kieny, M-P., Laustriat, D., Berthier, A., Mach, B., Montagnier, L., Lecocq, J-P., and Capron, A. (1989). Antibodies to the nef protein and to nef peptides in HIV-1-infected seronegative individuals. AIDS Res. Hum. Retroviruses 5, 279-291.
4. Bourgault, I., Venet, A., and Levy, J.P. (1992). Three epitopic peptides of the simian immunodeficiency virus Nef protein recognized by macaque cytolytic T lymphocytes. J. Virol. 66, 750-756.
5. Buge, S.L., Murty, L., Arora, K., Kalyanaraman, V.S., Markham, P.D., Richardson, E.S., Aldrich, K., Patterson, L.J., Miller, C.J., Cheng, S-M., and Robert-Guroff, M. (1999). Factors associated with slow disease progression in macaques immunized with an adenovirus-simian immunodeficiency virus (SIV) envelope priming-gp120 boosting regimen and challenged vaginally with SIVmac251 J. Virol. 73, 7430-7440. [Erratum: J. Virol. 73, 9692, 1999].
6. Buge, S.L., Richardson, E., Alipanah, S., Markham, P., Cheng, S., Kalyan, N., Miller, C.J., Lubeck, M., Udem, S., Eldridge, J., and Robert-Guroff, M. (1997). An adenovirus-simian immunodeficiency virus env vaccine elicits humoral, cellular, and mucosal immune responses in rhesus macaques and decreases viral burden following vaginal challenge. J. Virol. 71, 8531-8541.
7. Cafaro, A., Caputo, A., Fracasso, C., Maggiorella, M.T., Goletti, D., Baroncelli, S., Pace, M., Sernicola, L., Koanga-Mogtomo, M.L., Betti, M., Borsetti, A., Belli, R., Akerblom, L., Corrias, F., Butto, S., Heeney, J., Verani, P., Titti, F., and Ensoli, B. (1999). Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine. Nat. Med. 5, 643-650.
8. Calarota, S., Bratt, G., Nordlund, S., Hinkula, J., Leandersson, A.C., Sandstrom, E., and Wahren B. (1998). Cellular cytotoxic response induced by DNA vaccination in HIV-1 infected patients. Lancet 351, 1320-1325.
9. Cheng, S., Lee, S., Ronchetti-Blume, M., Virk, K.P., Mizutani, S., Eichberg, J.W., Davis, A., Hung, P.P., Hirsch, V.M., Chanock, R.M., Purcell, R.H., and Johnson, P.R. (1992). Coexpression of the simian immunodeficiency virus Env and Rev proteins by a recombinant human adenovirus host range mutant. J. Virol. 66, 6721-6725.
10. Collins, K.L., Chen, B.K., Kalams, S.A., Walker, B.D., and Baltimore, D. (1998). HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature 391, 397-401.
11. Cullen, B.R. (1994). The role of Nef in the replication cycle of the human and simian immunodeficiency viruses. Virology 205, 1-6.
12. De Maria, A., Cirillo, C., and Moretta, L. (1994). Occurrence of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T cell activity in apparently uninfected children born to HIV-1-infected mothers. J. Infect. Dis. 170, 1296-1299.
13. Gallimore A., Cranage, M., Cook, N., Almond, N., Bootman, J., Rud, E., Silvera, P., Dennis, M., Corcoran, T., Stott, J., Mcmichael, A., and Gotch, F. (1995). Early suppression of SIV replication by CD8+ nef-specific cytotoxic T cells in vaccinated macaques. Nat. Med. 1, 1167-1173.
14. Goldstein, G. (1996). HIV-1 Tat protein as a potential AIDS vaccine. Nat. Med. 2, 960-964.
15. Hinkula, J., Svanholm C., Schwartz, S., Lundholm, P., Brytting, M., Engstrom, G., Benthin, R., Glaser, H., Sutter, G., Kohleisen, B., Erfle, V., Okuda, K., Wigzell, H., and Wahren, B. (1997). Recognition of prominent viral epitopes induced by immunization with human immunodeficiency virus type 1 regulatory genes. J. Virol. 71, 5528-5539.
16. Jeang, K.T. (1994). HIV-1-tat: Structure and function. In Human Retroviruses and AIDS. G. Meyers, B. Korber, S. Wain-Hobson, K.T. Jeang, L.E. Henderson, and G.N. Pavlakis, eds. (Los Alamos National Laboratory, Los Alamos, NM). Part III, p. 11-20.
17. Kalyanaraman, V.S., Rodriguez, V., Veronese, F., Rahman, R., Lusso, P., De Vico, A.L., Copeland, T., Oroszlan, S., Gallo, R.C., and Sarngadharan, M.G. (1990). Characterization of the secreted, native gp120 and gp160 of the human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 6, 371-380.
18. Kaur, A., Yang, J., Hempel, D., Gritz, L., Mazzara, G.P., Mcclure, H., And Johnson, R.P. (2000). Identification of multiple simian immunodeficiency virus (SIV)-specific CTL epitopes in sooty mangabeys with natural and experimentally acquired SIV infection. J. Immunol. 164, 934-943.
19. Kestler, H.W., Ringler, D.J., Mori, K., Panicali, D.L., Sehgal, P.K., Sehgal, M.D., Daniel, M.D., and Desrosiers, R.C. (1991). Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell 65, 651-661.
20. Koenig, S., Conley, A.J., Brewah, Y.A., Jones, G.M., Leath, S., Boots, L.J., Davey, V., Pantaleo, G., Demarest, J.F., Carter, C., Wannebo, C., Yannelli, J.R., Rosenberg, S.A., and Lane, H.C. (1995). Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression. Nat. Med. 1, 330-336.
21. Korber, B., Brander, C., Haynes, B., Koup, R., Kuiken, C., Moore, J.P., Walker, B.D., and Watkins, D.I., eds. (2000). HIV Molecular Immunology. (Los Alamos National Laboratory, Theoretical Biology and Biophysics, Los Alamos, NM).
22. Langlade-Demoyen, P., Ngo-Giang-Huong, N., Ferchal, F., and Oksenhendler, E.J. (1994). Human immunodeficiency virus (HIV) nef-specific cytotoxic T lymphocytes in noninfected heterosexual contact of HIV-infected patients. J. Clin. Invest. 93, 1293-1297.
23. Lubeck, M.D., Natuk, R., Myagkikh, M., Kalyan, N., Aldrich, K., Sinangil, F., Alipanah, S., Murthy, S.C.S., Chanda, P.K., Nigida, S.M., Jr., Markham, P., Zollapazner, S., Steimer, K., Wade, M., Reitz, M., Jr., Arthur, L., Mizutani, S., Davis, A., Hung, P.P., Gallo, R.C., Eichberg, J., and Robert-Guroff, M. (1997). Longterm protection of chimpanzees against high-dose HIV-1 challenge induced by immunization. Nat. Med. 3, 651-658.
24. Montagnier, L. (1995). Nef vaccination against HIV disease. Lancet 346, 1170.
25. Mortara, L., Letourneur, F., Villefroy, P., Beyer, C., Gras-Masse, H., Guillt, J-G., and Bourgault-Villada, I. (2000). Temporal loss of Nef-epitope CTL recognition following macaque lipopeptide immunization and SIV challenge. Virology 278, 551-561.
26. Mothe, B.R., Horton, H., Carter, D.K., Allen, T.M., Liebl, M.E., Skinner, P., Vogel. T.U., Fuenger, S., Vielhuber, K., Rehrauer, W., Wilson, N., Franchini, G., Altman, J.D., Haase, A., Picker, L.J., Allison, D.B., and Watkins, D.I. (2002). Dominance of CD8 responses specific for epitopes bound by a single major histocompatibility complex class I molecule during the acute phase of viral infection. J. Virol. 76, 875-884.
27. Osterhaus, A.D.M.E., Van Baalen, C.A., Gruters, R.A., Schutten, M., Siebelink, C.H.J., Hulskotte, E.G.J., Tijhaar, E.J., Randall, R.E.R., Van Amerongen, G., Fleuchaus, A., Erfle, V., and Sutter, G. (1999). Vaccination with Rav and Tat against AIDS. Vaccine 17, 2713-2714.
28. Patterson, L.J., Robey, F., Muck, A., Van Remoortere, K., Aldrich, K., Richardson, E., Alvord, W.G., Markham, P.D., Cranage, M., and Robert-Guroff, M. (2001). A conformational C4 peptide polymer vaccine coupled with live recombinant vector priming is immunogenic but does not protect against rectal SIV challenge. AIDS Res. Hum. Retroviruses 17, 837-849.
29. Peng, B., and Robert-Guroff, M. (2001). Deletion of N-terminal myristoylation site of HIV Nef abrogates both MHC-1 and CD4 down-regulation. Immunol. Lett. 78, 195-200.
30. Piguet, V., and Trono, D. (1999). The Nef protein of primate lentiviruses. Rev. Med. Virol. 9, 111-120.
31. Ranki A., Lagerstedt, A., Ovod, V., Aavik, E., and Krohn, K.J. (1994). Expression kinetics and subcellular localization of HIV-1 regulatory proteins Nef, Tat and Rev in acutely and chronically infected lymphoid cell lines. Arch. Virol. 139, 365-378.
32. Richard, N., Iacampo, S., and Cochrane, A. (1994). HIV-1 Rev is capable of shuttling between the nucleus and cytoplasm. Virology 204, 123-131.
33. Robert-Guroff, M., Kaur, H., Patterson, L.J., Leno, M., Conley, A.J., Mckenna, P.M., Markham, P.D., Richardson, E., Aldrich, K., Arora, K., Murty, L., Carter, L., Zolla-Pazner, S., and Sinangil, F. (1998). Vaccine protection against a heterologous, non-syncytium-inducing, primary human immunodeficiency virus. J. Virol. 72, 10275-10280.
34. Robinson, S., Charini, W.A., Newberg, M.H., Kuroda, M.J., Lord, C.I., and Letvin, N.L. (2001). A commonly recognized simian immunodeficiency virus Nef epitope presented to cytotoxic T lymphocytes of Indian-origin rhesus monkeys by the prevalent major histocompatibility complex class I allele Mamu-A*02. J. Virol. 75, 10179-10186.
35. Singh, M.K., Janvier, G., Calvez, V., Coulaud, P., and Riviere, Y. (2001). A long-term follow-up of an HIV type 1-infected patient reveals a coincidence of Nef-directed cytotoxic T lymphocyte effectors and high incidence of epitope-deleted variants. AIDS Res. Hum. Retroviruses 17, 1265-1271.
36. Tahtinen, M., Strengell, M., Collings, A., Pitkanen, J., Kjerrtrom, A., Hakkarainen, K., Peterson, P., Kohleisen, B., Wahren, B., Ranki, A., Ustav, M., and Krohn, K. (2001). DNA vaccination in mice using HIV-1 nef, rev and tat genes in self-replicating pBN-vector. Vaccine 19, 20-39.
37. Van Baalen, C.A., Pontesilli, O., Huisman, R.C., Geretti, A.M., Klein, M.R., De Wolf, F., Miedema, F., Gruters, R.A., and Osterhaus, A.D.M.E. (1997). Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS. J. Gen. Virol. 78, 1913-1918.
38. Van Baalen, C.A., Schutten, M., Huisman, R.C., Boers, P.H.M., Gruters, R.A., and Osterhaus, A.D.M.E. (1998). Kinetics of antiviral activity by human immunodeficiency virus type 1-specific cytotoxic T lymphocytes (CTL) and rapid selection of CTL escape virus in vitro. J. Virol. 72, 6851-6857.
39. Venet, A., Bourgault, I., Aubertin, A.-M., Kieny, M-P., and Levy, J.-P. (1992). Cytotoxic T lymphocyte response against multiple simian immunodeficiency virus (SIV) proteins in SIV-infected macaques. J. Immunol. 148, 2899-2908.
40. Yasutomi, Y., Reimann, K.A., Lord, C.I., Miller, M.D., and Letvin, N.L. (1993). Simian immunodeficiency virus-specific CD8+ lymphocyte response in acutely infected rhesus monkeys. J. Virol. 67, 1707-1711.
41. Zagury, J.F., Sill, A., Blattner, W., Lachgar, A., Le Buanec, H., Richardson, J., Rappaport, J., Hendel, H., Bizzini, B., Gringeri, A., Carcagno, M., Criscuolo, M., Burny, A., Gallo, R.C., and Zagury, D. (1998). Antibodies to the HIV-1 Tat protein correlated with nonprogression to AIDS: A rationale for the use of Tat toxoid as an HIV-1 vaccine. J. Hum. Virol. 2, 282-292.
42. Zolla-Pazner, S., Lubeck, M., Xu, S., Burda, S., Natuk, R.J., Sinangil, F., Steimer, K., Gallo, R.C., Eichberg, J.W., Matthews, T., and Robert-Guroff, M. (1998). Induction of neutralizing antibodies to T-cell line-adapted and primary human immunodeficiency virus type 1 isolates with a prime-boost vaccine regimen in chimpanzees. J. Virol. 72, 1052-1059.